ФАРЬЕЛЛО Руджеро (CH),ФАРИНА Карло (IT),ГЕЛАРДИНИ Карла (IT)
申请号：
RU2013141926/15
公开号：
RU2013141926A
申请日:
2011.10.25
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. Application dimiratsetama or solvate thereof in the treatment and / or prevention of allodynia, in particular allodynia hands and / or feet, induced sorafenibom.2. Use according to claim 1, wherein it sorafenib administered or introduced in combination therapy with other antitumor chemotherapeutic agentami.3. Use according to claim 1, wherein sorafenib administered once, i.e., in the absence of other anti-cancer chemotherapeutic agentov.4. Application dimiratsetama or solvate thereof in combination with sorafenib and optionally with one or more other anticancer chemotherapeutic agents in the treatment raka.5. Use according to any one of claims 1 to 4, in which dimiratsetam is in the form of a mixture of (S) - and (R) -enantiomera.6. Use according to any one of claims 1 or 4 in a dosage for daily oral administration of from about 1 to about 100 mg / kg, preferably from about 8 to about 70 mg / kg, in particular from about 5 to about 65 mg / kg , or c dose to daily intramuscular administration of from about 5 to about 25 mg / kg, in particular from about 8 to about 20 mg / kg or a dose daily intravenous administration of from about 2 to about 20 mg / kg , in particular from 5 to 20 mg / kg, a dose or daily rectal administration of from about 8 g to about 70 mg / kg, preferably from 10 to 65 mg / kg, in particular from 5 to 35 mg / kg.7. Use according to any one of claims 1 or 4 in a dosage for daily administration including blood levels equal mikromolyarnyy.8 100-500. Use according to any one of claims 1 to 4 in the form of a medicament suitable for daily administration amount dimiratsetama pro- Kg, orally ravnogo-: Est1. Применение димирацетама или его сольвата при лечении и/или предупреждении аллодинии, в особенности, аллодинии кистей и/или стоп, индуцированной сорафенибом.2. Применение по п.1, в котором сорафениб вводят или он был введен в комбинационной терапии с другими противоопухолевыми химиотерапевтическими агентами.3. Применение по п.1, в котором вводят од
